Thierry Alcindor

Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada.

Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada.

Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada.

Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada.

Esperas Pharma, Inc. manufactures and develops pharmaceutical products. The firm is created to develop one compound to proof-of-concept. It plans to develop, to proof-of-concept, a compound originally discovered through one of Lilly’s research and development programs, with the potential to treat certain types of cancers including triple negative breast cancer. The company was founded in 2015 and is headquartered in Montreal, Canada.